FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     McWherter Charles					2. Issuer Name and Ticker or Trading Symbol  CymaBay Therapeutics, Inc. [ CBAY ]										5. Relationship of Reporting Person(s) to Is (Check all applicable)  Director 10				ner	
(Last)	(First)	) (I	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/25/2023							X	Officer (gi	ve title		Other (s below)	pecify		
C/O CYMABAY THERAPEUTICS, INC.															President of R&D					
7575 GATEWAY BLVD., SUITE 110					4. If Amendment, Date of Original Filed (Month/Day/Year)								- 1	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person						
Street) NEWARK CA 94560													X	Form filed by More than One Reporting Person						
(City)	(State	e) (2	Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date				ansaction th/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispos			ırities Acquired (A) or ed Of (D) (Instr. 3, 4 a			Following I	curities Forn or In lowing Reported insaction(s)		Direct (D) lirect (I) 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount (A) or (D)		Price	(Instr. 3 and								
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Co	Transaction Code (Instr.				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		erlying	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Cod	de	v	(A)	(D)	Date Exercisab		epiration ate	Title		Amount or Number of Shares		(Instr. 4)				
Employee Stock Option (right to buy)	\$7.8	01/25/2023			A		300,000		(1)	01	/24/2033	Comr Stoo		300,000	\$0	300,00	0	D		

## Explanation of Responses:

1. The option vests as to 1/48 of the underlying shares monthly from January 1, 2023.

/s/ Sujal Shah, as attorney-in-fact for Charles McWherter

01/26/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).